However, 10 of the government drug advisers who supported the continuance of Vioxx were in some way tied financially to the drug. Without their votes, the committee would have voted that Vioxx should not return to the market. Response Personally, I was shocked by the Merck/Vioxx situation. I could not believe that something that was basically proven to cause heart attacks and strokes was permitted to be put on the market in the first place, and the fact that it may be brought back is horrible...
displayed 300 characters

Pay now and get a FULL UNLIMITED access! This option entitles you to get access to a huge database of 200.000 essay papers. You receive a possibility of full access and of viewing an unlimited number of essays for a fair price! Any subject, any topic and any level of difficulty of a paper - anything can be found here.   No limitations and no restrictions with EssaysBank.com, since our aim is to help you with your essay writing. A huge database of supplementary materials for your research and for better understanding of the topic costs so few! Use your chance to make a better research and to receive a higher grade!

I could not believe that something that was basically proven to cause heart attacks and strokes was permitted to be put on the market in the first place, and the fact that it may be brought back is horrible. I believe that things are being handled terribly. Since so many of the members of the committee are financially connected with Merck & Co...
displayed next 300 characters

Title	Pages / Words	Save
Merck & Company: Evaluating a drug licensing opportunity Using the probability of 14.55%, which is the combined probability for any sucess, I recalculated the valuations of each success (Depression only, Depression only after testing for both in phase III, Weight only, etc)...	4 / 887
Merck&Company: Evaluating a Drug Licensing Opportunity Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions: All Cash flows are expressed as after tax present values discounted to time zero, including capital expenditures At any point "failure," investment decision is to stop funding Assuming Standard deviation of 0...	2 / 301
Merck&Company We can rationalize not using DCF for its inability to capture risk uncertainty. Passive investments such as stocks and bonds are good candidates to use DCF on...	4 / 875
Merck First, the company is facing a serious situation that most of their patents are going to expire soon, and the company's value and profits are declining, so it is necessary to invest in new drug developments...	12 / 3181